Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...

Johnson & Johnson (NYSE:JNJ) is reportedly suing Samsung Bioepis for breach of contract related to the launch of a biosimilar ...

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Ustekinumab products may increase the risk of infections and reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections were observed in patients receiving ...

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

Basel, February 24, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US.From today, the ...

Pyzchiva® offers an affordable option for patients who could benefit from treatment with ustekinumab. It also provides the full suite of dosing options to meet the needs of a variety of patients ...